Status:
COMPLETED
Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in Japan
Lead Sponsor:
Ono Pharmaceutical Co. Ltd
Conditions:
Parkinson's Disease
Eligibility:
All Genders
20-79 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of ONO-2506PO in patients with Parkinson's Disease
Eligibility Criteria
Inclusion
- Diagnosis of Parkinson's disease
- Stage 2 - Stage 4 of revised Hoehn \& Yahr severity score
- Taking L-dopa/DCI without changing dose and regimen
- Having motor complication
- Other inclusion criteria as specified in the study protocol
Exclusion
- Previous participation in ONO-2506PO or ONO-2506 protocol
- Previous brain surgery for Parkinson's disease
- Presence or history of serious cardiac disease
- Other exclusion criteria as specified in the study protocol
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
165 Patients enrolled
Trial Details
Trial ID
NCT00212693
Start Date
January 1 2004
Last Update
October 11 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.